| J-11 | J-12 | J-13 | J-14 | J-15 | J-17 |
---|---|---|---|---|---|---|
Sex | F | F | M | F | F | F |
Race | White | White | White | White | Asian | Asian |
Age of onset | 2 | 15 | 12 | 1 | 7 | 5 |
JIA category | Oligo | Poly | Oligo | Poly | Oligo | Oligo |
Joint Count | 1 | 18 | 2 | 17 | 1 | 1 |
Patient global assessment | 4 | 9.5 | 4 | 4 | 1 | 2 |
Physician global assessment | 3 | 6 | 6 | 9 | 2 | 2 |
CHAQ | 1.12 | 2.30 | 0.25 | 2.12 | 0 | 2 |
JADAS-27 | 8 | 33.5 | 16.5 | 30.9 | 5 | 9 |
ANA | Negative | 1:320 | Negative | Negative | 1:320 | Negative |
RF | ND | Negative | Negative | Negative | Negative | Negative |
CCP status | Negative |  > 250 | Negative | Negative | 80 | Negative |
B27 | ND | Negative | Negative | Negative | Negative | Negative |
Medications | Naproxen | Naproxen | None | Allergy med* | None | None |